AXXE | Axxess Pharma, Inc. & Extended Watchlist

Axxess Pharma, Inc. AXXE
–
We’re touching base with AXXE again this morning, as the company has made some exciting announcements over the past couple of days including the acquisition of assets previously belonging to Revive Bioscience Inc., a Canadian OTC healthcare company, a move that widens AXXE’s catalog of pharma products significantly. Even more exciting is the fact that Revive held the rights to several branded OTC products endorsed by professional athletes in many major American sports including the NFL, NHL, and more.
–

Additionally, in a PR from yesterday we learned that AXXE has also made an addition to an already strong management team, with the appointment of Robert Tallack, who will serve as VP of Sales and Marketing. You can read more in depth about both developments by clicking through the press links below, but first, we’re going to take a look at how the AXXE chart is faring via the following video:

Be sure to check out the Exclusive Interview our sister site, Stock Traders Talk, conducted with AXXE President Dr. Daniel Bagi last week:
AXXE Interview

You can also take a look at our initial report on the company:
AXXE Report

Extended Watchlist:
FREE, DRYS, GOGO, RAD

GRNH, Options Trading Ideas & Extended Watchlist

Aeropostale, Inc. ARO

The 10/19 $9 Calls that we mentioned yesterday morning opened up significantly as we expected they would. After the subsequent consolidation which brought the price back to 1.05, we saw a spike to as much as 1.55 as you can see on the chart below. That was good for a possible intraday gain of 48%

With roughly a month left until the expiration of these contracts, there’s plenty of time for the stock to regain some of its recently lost ground and potentially fill the gap on the chart up to the $11-range. With the kind of drastic stride it made yesterday (jumping from the $8-range to the $10-range) we’ll also need to be wary of possible pullbacks filling that gap to the downside.

Facebook Inc. FB

As FB has recently been approaching its 52-week highs, we’re interested in weekly Calls, especially if the stock can break the $46 barrier. In that event, we’d be looking at in-the-money Calls like the 09/21 $45.50’s. On the flipside, if the stock fails to push past $46 we would be looking to flip the $46 Puts as a pullback would push them in-the-money.

GreenGro Technologies GRNH

This is another marijuana related stock that we’ve tracked for quite some time. GRNH has made some nice moves over the past several weeks, and is currently in consolidation mode as it has been coming off of its most recent spike. We are keeping a close eye on this one for a potential bottom play. If it can maintain support above the 50DMA of .042 we like its chances of seeing a nice rebound in the future.

Extended Watchlist:
NEWL, DNDN, ATOS, ZQK, IDRA, PCWT

ARO, RMTI, PHOT & Extended Watchlist

Aeropostale, Inc. ARO

At the beginning of August, ARO began to experience a substantial sell-off that would cause the stock to fall from the $15-range to less than $8 at the beginning of this month. We are standing at the ready this morning as we’ve observed some northward pre-market trading, with shares changing hands for as much as 10.13. The significant gaps on the chart being filled could provide not only opportunities on the stock side of things, but in the trading of options contracts as well.

The 10/19 $9.00 Calls are of particular interest to us; Closing at .35 yesterday, and with this morning’s gap-up activity, these calls could open up as much as 100%  In that event, we would be looking for a consolidation before getting our feet wet.

Rockwell Medical, Inc. RMTI

RMTI would make a nice intraday move for us after its appearance in yesterday’s morning report, running from a low of 8.75 and reaching its peak at 11.80, good enough for a 35% gain.

Following the high, the stock came back as low as 9.85. Moving we are looking for the stock to hold support at its previous swing low of 8.75. In the meantime the company released an encouraging PR today announcing the completion of an important step in getting a new kidney drug to market, that appears to be contributing to yet another gap-up situation today.

WIXOM, MI–(Marketwired – Sep 17, 2013) – Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, today announced the U.S. Food & Drug Administration (FDA) accepted the proposed proprietary trade name Triferic™ for the Company’s investigational iron-delivery drug, previously known as Soluble Ferric Pyrophosphate (SFP), which is intended for treating iron deficiency in chronic kidney disease patients receiving hemodialysis. A request for proprietary name review for Triferic™ will be filed with the New Drug Application (NDA) submission.>>>FULL STORY

GroLife, Inc. PHOT

We had another gainer in PHOT yesterday, as the stock jumped from .046 to .061, affording us the opportunity at a 33% intraday rip. Since 08/30 when we re-mentioned PHOT, it has been as low as .0318, which makes yesterday’s high a move of 93%

For almost a year now, we’ve placed a strong focus on marijuana-related stocks, publishing several reports, and doing the most recent followup at the end of August. The industry has, and we believe, will continue to bring us profits in the future. It’s for that reason we suggest everyone keep a marijuana stock watchlist of their own. We have only just begun to realize the potential for this up-and-coming sector, which is certain to be a high-growth area for years to come.

Extended Watchlist:
AGEN, NBS, BCRX, RGDO, SUTR, DNDN, MATR, SD